Lawmakers hone in on PBM problems. More good news about vaccines. (890 words, 4 minutes, 27 seconds) Lawmakers highlight PBM abuses as they grill insurance CEOs While they differed on root causes for ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on changes announced to the US childhood vaccine schedule.

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA ...

WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented ...

A new BIO report outlines the state of early-stage funding for biotechs. Plus, during BIO 2025, legal experts unpacked IRA litigation—here’s what you should know. (761 words, 3 minutes, 48 seconds) ...

It's Day 4. We recap a few impactful sessions exploring why patients – including rare disease patients and women – can't wait. Today, we close out with a look at how we can ensure the virtuous cycle ...

WASHINGTON, D.C. - John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s dismissal of the voting members of the CDC ...

Washington, DC, May 28, 2025 – The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work of its Agriculture and ...

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the ...

BIO launches a new campaign to explain why we vaccinate – and why it's good for America. We have details, plus how drug companies are investing in U.S. manufacturing, news on drug prices and IP, and ...

Today, we have details on the National Security Commission on Emerging Biotechnology’s new report—and why tariffs still threaten biotech, including pharma and ag. (816 words, 4 minutes, 4 seconds) ...